Advances in sarcoma gene mutations and therapeutic targets. (January 2018)

• Record Type: Journal Article
• Authors: Gao, Peng; Seebacher, Nicole A.; Hornicek, Francis; Guo, Zheng; Duan, Zhenfeng
• Is Part Of: Cancer treatment reviews. Volume 62(2018)
• Page Start: 98
• Page End: 109
• Publication Date: 2018-01
• Subjects: Sarcoma -- Gene mutation -- P53 -- RB -- PI3K -- IDH -- Targeted therapy; Cancer -- Periodicals; Cancer -- Treatment -- Periodicals; Neoplasms -- therapy -- Periodicals; Cancer -- Périodiques; Cancer -- Traitement -- Périodiques; Cancer -- Treatment; Electronic journals; Periodicals; 616.99406
• DOI: 10.1016/j.ctrv.2017.11.001
• Languages: English
• ISSNs: 0305-7372

Abstract

Highlights: Specific gene mutations are important in driving the pathogenesis and progression of sarcomas. p53, RB, PI3K and IDH gene mutations are the most prevalent mutations identified in sarcomas. Gene mutation based preclinical studies and clinical trials in using targeted therapies may improve the treatment of sarcoma patients. Abstract: Sarcomas are rare and complex malignancies that have been associated with a poor prognostic outcome. Over the last few decades, traditional treatment with surgery and/or chemotherapy has not significantly improved outcomes for most types of sarcomas. In recent years, there have been significant advances in the understanding of specific gene mutations that are important in driving the pathogenesis and progression of sarcomas. Identification of these new gene mutations, using next-generation sequencing and advanced molecular techniques, has revealed a range of potential therapeutic targets. This, in turn, may lead to the development of novel agents targeted to different sarcoma subtypes. In this review, we highlight the advances made in identifying sarcoma gene mutations, including those of p53, RB, PI3K and IDH genes, as well as novel therapeutic strategies aimed at utilizing these mutant genes. In addition, we discuss a number of preclinical studies and ongoing early clinical trials in sarcoma targeting therapies, as well as gene editing technology, which may provide a better choice for sarcoma patient management.